Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

Ki vehet részt

• Male and female outpatients ≥ 18 and ≤ 65 years of age at Screening
• Patients with the diagnosis of Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) ADHD, as determined by clinical evaluation and confirmed by structured interview (MINI)
• Adequate organ function
• Able to understand the study procedures and understand risks associated with the study, and sign written informed consent to participate in the study
• Must be willing to refrain from more than 6 standard alcoholic drinks a week, more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete

Ki nem vehet részt

• Once Informed Consent form is signed, not willing or able to stop any prescription or non-prescription ADHD medications
• Use of investigational medication/treatment in the past 30 days
• Patients with a positive urine drug screen with the exception of THC or its metabolites
• Past or present diagnosis of a primary psychotic disorder or first degree relative with a psychotic disorder
• Past or present bipolar disorder (DSM-5)
• Any lifetime history of suicide attempt
• Pregnant or nursing females